The response of UBXN2A haploinsufficient mice to VTD, which closely mimics the ~ 50% CRC patients with low UBXN2A levels (10), supporting the drug-likeness of VTD as a potent inhibitor of Rictor-mTORC2 tumorigenic pathways in CRC. The gene discussed is UBXN2A; the disease is colorectal carcinoma.